Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.

ABSTRACT:

Background and objectives

Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD.

Design, setting, participants, & measurements

We conducted a prospective cohort study of 3869 individuals with mild to severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anem

SUBMITTER: Mehta R 

PROVIDER: S-EPMC5672973 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature